MARTINA, Valentino
 Distribuzione geografica
Continente #
NA - Nord America 1.415
EU - Europa 971
AS - Asia 554
AF - Africa 52
OC - Oceania 3
SA - Sud America 2
Totale 2.997
Nazione #
US - Stati Uniti d'America 1.403
CN - Cina 330
IT - Italia 141
IE - Irlanda 139
SE - Svezia 138
UA - Ucraina 135
SG - Singapore 120
FR - Francia 103
DE - Germania 88
FI - Finlandia 86
KR - Corea 83
SN - Senegal 47
GB - Regno Unito 46
PL - Polonia 34
AT - Austria 29
BE - Belgio 13
CA - Canada 12
VN - Vietnam 9
GR - Grecia 6
NL - Olanda 5
MU - Mauritius 4
AU - Australia 3
ES - Italia 3
IN - India 3
BR - Brasile 2
RO - Romania 2
SY - Repubblica araba siriana 2
AL - Albania 1
AM - Armenia 1
DZ - Algeria 1
HK - Hong Kong 1
IQ - Iraq 1
NO - Norvegia 1
PH - Filippine 1
PS - Palestinian Territory 1
RU - Federazione Russa 1
TR - Turchia 1
UZ - Uzbekistan 1
Totale 2.997
Città #
Beijing 279
Chandler 220
Houston 150
Santa Clara 150
Dublin 139
Singapore 88
Villeurbanne 70
Jacksonville 64
Ann Arbor 60
Dearborn 60
Ashburn 59
Princeton 57
Nyköping 45
Medford 42
Columbus 37
Warsaw 32
Milan 29
Vienna 29
Wilmington 29
Boston 20
Boardman 16
Verona 13
Torino 12
Brussels 11
Detroit 9
Norwalk 9
Woodbridge 9
Fairfield 8
Fremont 8
Washington 8
Kunming 7
Toronto 7
Hefei 6
Dong Ket 5
Falls Church 5
Lachine 5
Mountain View 5
Rome 5
Nanjing 4
Nuremberg 4
Redwood City 4
San Mateo 4
Shanghai 4
Chicago 3
Jinan 3
Vicenza 3
Botosani 2
Dongguan 2
Fort Worth 2
Frankfurt am Main 2
Gent 2
Guangzhou 2
Kraków 2
Los Angeles 2
Munich 2
Philadelphia 2
Pune 2
Shenyang 2
Silver Spring 2
Alghero 1
Ambrogio 1
Augusta 1
Ballabio 1
Bari 1
Brescia 1
Cagliari 1
Cambridge 1
Castiglione D'adda 1
Changsha 1
Denver 1
Des Moines 1
Diadema 1
Edinburgh 1
Forlì 1
Fuzhou 1
Guiyang 1
Hangzhou 1
Hebei 1
Hong Kong 1
Jingmen 1
Kirkuk 1
Lianyun 1
London 1
Maddaloni 1
Milazzo 1
Moncalieri 1
Nanchang 1
Ningbo 1
Oslo 1
Purley 1
Quzhou 1
Ramallah 1
Redcar 1
Redmond 1
Salerno 1
San Marcello 1
Seattle 1
Strasbourg 1
São Paulo 1
Taizhou 1
Totale 1.903
Nome #
Nel soggetto normale la ferritemia correla con l’HOMA. 119
Ghrelin secretion is inhibited by glucose load and insulin-induced hypoglycaemia but unaffected by glucagon and arginine in humans 115
Blunted GH response to growth hormone-releasing hormone (GHRH) alone or combined with arginine in non-insulin-dependent diabetes mellitus. 113
Pirenzepine decreases basal and stimulated GH secretion in patients with type 2 (non-insulin-dependent) diabetes mellitus. 110
Repeated administration of growth hormone-releasing hormone with or without previous administration of pyridostigmine in insulin-dependent diabetes mellitus. 108
Inhibition by salbutamol of GHRH-induced GH release in type 1 diabetes mellitus. 108
Comparison of Monotard and Ultratard insulin at bedtime in a model of optimized insulin therapy in Italy. 104
Clinical and genetic variability in XX sex-reversed patients. 97
Ghrelin and synthetic growth hormone secretagogues are cardioactive molecules with identities and differences 94
The altered plasma amino acid pattern is responsible for the paradoxical growth hormone response to the oral glucose tolerance test in liver cirrhosis. 91
Interaction of free fatty acids and arginine on growth hormone secretion in man. 91
GHRELIN SECRETION IS INHIBITED BY GLUCOSE LOAD AND INSULIN-INDUCED HYPOGLYCEMIA BUT UNAFFECTED BY GLUCAGON AND ARGININE IN HUMANS 85
N-acetylcysteine is able to reduce the oxidation status and the endothelial activation after a high-glucose content meal in patients with type 2 diabetes mellitus 82
Pirenzepine blunts the nocturnal growth hormone release in insulin dependent diabetes. 81
FEMALE PATIENTS WITH DOWN SYNDROME (DS) SHOW A GREATER INSULIN RESISTANCE IN COMPARISON WITH NORMAL FEMALES (NF) 80
Chronic treatment with pirenzepine decreases growth hormone secretion in insulin-dependent diabetes mellitus. 79
Dehydroepiandrosterone positively affects nitric oxide production in platelets of normal subjects. 77
L-Arginine 75
Bone metabolism in type 2 diabetes mellitus 70
PATIENTS WITH DOWN’S SYNDROME (DS) ARE INSULIN RESISTANT INDEPENDENTLY OF BODY MASS INDEX (BMI) 70
Administration of glutathione in patients with type 2 diabetes mellitus increases the platelet constitutive nitric oxide synthase activity and reduces PAI-1. 69
DHEAS and platelet cGMP variations during lifespan. 64
La produzione di ossido nitrico si riduce con l’età e correla con il DHEAS e l’IGF-I nel soggetto normale. 63
Platelet cGMP inversely correlates with age in healthy subjects. 63
Platelet cGMP inversely correlates with age in healthy subjects 62
Deydroepiandrosterone positevely affects nitric oxide production in the platelets of normal subjects. 62
METABOLIC ACTIONS OF GHRELIN 62
Long-term N-acetylcysteine and L-arginine administration reduces endothelial activation and systolic blood pressure in hypertensive patients with type 2 diabetes. 61
Short-term dehydroepiandrosterone treatment increases platelet cGMP production in elderly male subjects 60
La ferritinemia: possibile marker di insulino resistenza. 58
I livelli plasmatici di dHEAS influenzano la produzione di cGMP piastrinico nel soggetto normale e nel soggetto affetto da DM T2. 58
In normal subjects HOMA positively correlates with serum ferritin, a cardiovascular risk factor. 58
Serum DHEAS levels correlate with platelet cGMP in normal women 57
Multiple endocrine neoplasia (MEN IIB) with Cushing's syndrome due to medullary thyroid carcinoma producing corticotropin-releasing hormone. 52
Prolonged treatment with N-acetylcysteine and L-arginine restores gonadal function in patients with polycystic ovary syndrome 52
Platelet cyclic guanosine monophosphate production during menstrual cycle in healthy women. 50
Platelet cNOS activity is reduced in patients with IDDM and NIDDM. 47
Plasma DHEAS levels affect the platelet cGMP in normal subjects and in diabetic type 2 patients. 47
Role of the Decreased Nitric Oxide Bioavailability in the Vascular Complications of Diabetes Mellitus. 45
Transdermal oestradiol replacement therapy enhances platelet constitutive nitric oxide synthase activity in postmenopausal women with type 2 diabetes mellitus. 42
N-acetylcysteine is able to reduce the oxidation status and the endothelial activation after a high-glucose content meal in patients with Type 2 diabetes mellitus 41
Plasma DHEAS levels affects the intraplatelet cGMP synthesis in normal subjects and in diabetic type 2 patients. 40
Nitric Oxide production declines with age and correlates with DHEAS and IGF-1 in normal man. 33
Totale 3.095
Categoria #
all - tutte 10.170
article - articoli 0
book - libri 0
conference - conferenze 3.378
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 13.548


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202087 0 0 0 0 0 0 0 13 25 18 24 7
2020/2021261 44 8 34 6 40 7 25 5 31 29 10 22
2021/2022301 5 5 6 8 19 6 23 22 11 27 69 100
2022/2023572 76 37 17 58 50 176 47 37 41 5 24 4
2023/2024212 18 44 17 20 14 34 7 5 0 7 8 38
2024/2025374 4 23 9 55 238 18 20 7 0 0 0 0
Totale 3.095